RxDoctor Payments Data

Laura Voicu, MD

Ophthalmology · Boston, MANPI 1871889428

Payments from drug & device makers

$6,778in general payments, 2019–2025

Across 86 payments — averaging $78.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$4K
  • Sun Pharmaceutical Industries Inc.$295
  • Alcon$274
  • Novartis$242
  • Aerie Pharmaceuticals, Inc.$232
  • Bausch & Lomb Americas Inc.$231
  • plus $1K from 16 others
$10,000in research payments, 2019–2025

Across 2 payments — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • NEW World Medical,inc.$10K

What the payments were for

  • Speaking & faculty fees$3,35049%
  • Food & beverage$3,33849%
  • Gifts$901%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,778 in reported general payments places this provider in the 80th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$252,124
Medicare patients
702
Services billed
2,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine111$99,613
XiidraLifitegrast47$44,527
Cyclosporine70$37,987
CequaCyclosporine38$26,509
RocklatanNetarsudil Mesylat/Latanoprost14$11,942
RhopressaNetarsudil Mesylate31$11,206
TyrvayaVarenicline Tartrate14$9,539
Methazolamide28$6,457
SimbrinzaBrinzolamide/Brimonidine Tart16$6,369
TafluprostTafluprost/Pf26$5,904
Timolol MaleateTimolol Maleate/Pf15$4,529
Prednisolone Acetate130$4,280
Latanoprost452$4,268
Dorzolamide-TimololDorzolamide/Timolol/Pf22$3,912
Brimonidine Tartrate169$3,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$163$99,613111 claims
Bausch & Lomb Americas Inc.Xiidra$231$44,52747 claims
Sun Pharmaceutical Industries Inc.Cequa$295$26,50938 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$232$23,14845 claims
Oyster Point Pharma, Inc.Tyrvaya$99$9,53914 claims
AlconSimbrinza$274$6,36916 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$31$1,79116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →